EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access

An eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Patients With Metastatic Cancers: Protocol for a Randomized Trial

Kimberley T Lee iD, Briana McLeod iD, Brian Egleston iD, Sarah Brown iD, Sarah Howe iD, Dominique Fetzer iD, Lauren Gutstein iD, Cara Cacioppo iD, Dana Clark iD, Susan M Domchek iD, Jessica Ebrahimzadeh iD, Dana Falcone iD und 13 weitere

JMIR Research Protocols · 2025

DOI: 10.2196/72515 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JMIR Research Protocols, 2025. Verfasst von Kimberley T Lee und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, United States. Hauptthemen laut MEDLINE: Genetic Testing, Genetic Predisposition to Disease, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Germline BRCA1 and BRCA2 testing is a standard evidence-based practice, with established risk reduction and cancer screening guidelines for genetic carriers. With Food and Drug Administration approval for poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors in patients with metastatic breast, ovarian, pancreatic, and prostate cancer, there is an additional therapeutic rationale for testing all patients with these cancers for germline BRCA1 and BRCA2 mutations. However, many at-risk patients do not have access to genetic services, leaving many genetic carriers unidentified.

Objective

The eREACH (A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate, and Pancreatic Cancer Patients) study evaluates the effectiveness of a theoretically and stakeholder-informed eHealth (eg, digital) delivery alternative to traditional genetic counseling for patients with metastatic breast or prostate cancer or advanced or metastatic ovarian or pancreatic cancer referred for genetic testing to determine whether they are candidates for a PARP inhibitor.

Methods

The eREACH study is a randomized noninferiority study using a 2 × 2 design to test a self-directed digital intervention to deliver clinical genetic testing for patients with metastatic cancers. The traditional standard-of-care pretest (visit 1) and posttest (visit 2—disclosure) counseling delivered by a genetic counselor is replaced with our patient-informed digital intervention. The four arms were as follows: arm A, genetic counselor for visits 1 and 2; arm B, genetic counselor for visit 1 and digital intervention for visit 2; arm C, digital intervention for visit 1 and genetic counselor for visit 2; and arm D, digital intervention for both visits. Participants were adults with advanced or metastatic breast, ovarian, pancreatic, and prostate cancer. The primary outcomes of this study were change in genetic knowledge and anxiety from baseline to postdisclosure assessment. We will test whether the digital intervention is noninferior to standard-of-care counseling with a genetic counselor using a modified noninferiority ANOVA of the posttest disclosure minus baseline change scores. In secondary analyses, we will test pairwise differences among the 4 groups.

Results

As of January 2025, we have completed enrollment of 229 participants. Data analysis is ongoing, and we expect the results to be published in 2025.

Conclusions

Increasing indications for BRCA1 and BRCA2 testing create a pressing need to evaluate alternative delivery models to increase access and uptake of these tests while maintaining adequate patient cognitive, affective, and behavioral outcomes. The eREACH study evaluates the effectiveness of an interactive, patient-centered digital intervention to deliver clinical genetic testing to patients with metastatic cancers. We expect that this work will inform evidence-based guidelines and the standard of care for delivery of genetic testing, and it is designed to be broadly applicable and easily adaptable for other populations and settings even beyond oncology. Trial Registration ClinicalTrials.gov NCT04353973; https://clinicaltrials.gov/study/NCT04353973 International Registered Report Identifier (IRRID) DERR1-10.2196/72515

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingGenetic Predisposition to DiseaseNeoplasmsHumansFemaleMaleTelemedicineRandomized Controlled Trials as TopicPancreatic NeoplasmsNeoplasm MetastasisBreast NeoplasmsGenetic CounselingOvarian NeoplasmsBRCA2 ProteinAdultProstatic NeoplasmsBRCA1 ProteinMiddle AgedEquivalence Trials as Topic

Stichwörter der Autor:innen

digital healthgenetic counselinggenetic testingmetastatic cancer, digital genetic education

Substanzen

BRCA2 ProteinBRCA1 Protein

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States.
  • Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA, United States.
  • Department of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest School of Medicine, Winston Salem, NC, United States.
  • Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, United States.
  • Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, United States.

ORCID-Profile: Kimberley T Lee, Briana McLeod, Brian Egleston, Sarah Brown, Sarah Howe, Dominique Fetzer, Lauren Gutstein, Cara Cacioppo, Dana Clark, Susan M Domchek, Jessica Ebrahimzadeh, Dana Falcone, Demetrios Ofidis, Hannah Griffin, Rajia Mim, Santina Hernandez, Linda Fleisher, Kelsey Karpink, Enida Selmani, Aysha Tahsin, Lynne Wagner, Michelle Weinberg, Kuang Yi-Wen, Elisabeth Wood, Angela R Bradbury

Förderung

  • NCI NIH HHS

Zitieren

APA

Lee, K. T., McLeod, B., Egleston, B., Brown, S., Howe, S., Fetzer, D., Gutstein, L., Cacioppo, C., Clark, D., Domchek, S. M., Ebrahimzadeh, J., Falcone, D., Ofidis, D., Griffin, H., Mim, R., Hernandez, S., Fleisher, L., Karpink, K., Selmani, E., …, & Bradbury, A. R. (2025). An eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Patients With Metastatic Cancers: Protocol for a Randomized Trial. JMIR Research Protocols. https://doi.org/10.2196/72515

Vancouver

Lee KT, McLeod B, Egleston B, Brown S, Howe S, Fetzer D, et al. An eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Patients With Metastatic Cancers: Protocol for a Randomized Trial. JMIR Research Protocols. 2025. doi:10.2196/72515

BibTeX
@article{Lee2025,
  author = {Lee, Kimberley T and McLeod, Briana and Egleston, Brian and Brown, Sarah and Howe, Sarah and Fetzer, Dominique and Gutstein, Lauren and Cacioppo, Cara and Clark, Dana and Domchek, Susan M and Ebrahimzadeh, Jessica and Falcone, Dana and Ofidis, Demetrios and Griffin, Hannah and Mim, Rajia and Hernandez, Santina and Fleisher, Linda and Karpink, Kelsey and Selmani, Enida and Tahsin, Aysha and Wagner, Lynne and Weinberg, Michelle and Yi-Wen, Kuang and Wood, Elisabeth and Bradbury, Angela R},
  title = {An eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Patients With Metastatic Cancers: Protocol for a Randomized Trial},
  journal = {JMIR Research Protocols},
  year = {2025},
  doi = {10.2196/72515}
}
Kostenlos starten →